Highlights and Quick Summary
- Common Stock (Net) for the quarter ending June 30, 2022 was $50 Thousand (a 2.04% increase compared to previous quarter)
- Year-over-year quarterly Common Stock (Net) increased by 4.17%
- Annual Common Stock (Net) for 2021 was $48 Thousand (a 65.52% increase from previous year)
- Annual Common Stock (Net) for 2020 was $29 Thousand (a 0.0% decrease from previous year)
- Annual Common Stock (Net) for 2019 was $29 Thousand (a 16.0% increase from previous year)
Visit stockrow.com/PHAS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Common Stock (Net) of PhaseBio Pharmaceuticals
Most recent Common Stock (Net)of PHAS including historical data for past 10 years.Interactive Chart of Common Stock (Net) of PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals Common Stock (Net) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | $0.05 | $0.05 | – | – | – |
2021 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 |
2020 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 |
2019 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 |
2018 | $0.03 | $0.0 | $0.0 | $0.0 | $0.03 |
2017 | – | – | – | $0.0 | $0.01 |
2016 | – | – | – | – | $0.01 |
Business Profile of PhaseBio Pharmaceuticals
Sector: Healthcare
Industry: Biotechnology